At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRTG Portage Biotech Inc.
Post-Market Trading 09-19 18:12:15 EDT
10.21
+0.30
+3.03%
盘后9.82
-0.39-3.82%
18:10 EDT
High12.93Low8.27Vol2.47M
Open11.64D1 Closing9.91Amplitude47.02%
Mkt Cap10.71MTradable Cap5.38MTotal Shares1.05M
T/O27.16MT/O Rate469.95%Tradable Shares526.60K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Portage Biotech Regains Nasdaq Compliance
TIPRANKS  ·  09-04
Portage Biotech Regains Nasdaq Compliance
Portage Biotech : Regains Compliance With Nasdaq Listing Rule 5550(a)(2)
THOMSON REUTERS  ·  09-04
Portage Biotech : Regains Compliance With Nasdaq Listing Rule 5550(a)(2)
Portage Biotech Shares Down 2.5%
THOMSON REUTERS  ·  08-28
Portage Biotech Shares Down 2.5%
Portage Biotech Shares Fall 6.1% Premarket
THOMSON REUTERS  ·  08-28
Portage Biotech Shares Fall 6.1% Premarket
Portage Biotech Shares Down 3.1% After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
THOMSON REUTERS  ·  08-27
Portage Biotech Shares Down 3.1% After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
Portage Biotech Reports Decreased Quarterly Loss
TIPRANKS  ·  08-27
Portage Biotech Reports Decreased Quarterly Loss
Portage Biotech Shares Down 4.2% Premarket After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
THOMSON REUTERS  ·  08-27
Portage Biotech Shares Down 4.2% Premarket After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
Portage Biotech Q2 EPS $(1.58) Up From $(6.69) YoY
Benzinga  ·  08-27
Portage Biotech Q2 EPS $(1.58) Up From $(6.69) YoY
Portage Biotech Inc - Exploring Strategic Alternatives Including a Sale of Co, Merger, Restructurings, Company Wind Down
THOMSON REUTERS  ·  08-27
Portage Biotech Inc - Exploring Strategic Alternatives Including a Sale of Co, Merger, Restructurings, Company Wind Down
Portage Biotech Inc: Continue to Explore Strategic Alternatives
THOMSON REUTERS  ·  08-27
Portage Biotech Inc: Continue to Explore Strategic Alternatives
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
THOMSON REUTERS  ·  08-27
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
Portage Biotech Inc- Qtrly Shr Loss $1.58
THOMSON REUTERS  ·  08-27
Portage Biotech Inc- Qtrly Shr Loss $1.58
Portage Biotech- Plan to Replace 1 Patient in Adport-601 Trial Who Withdrew Prior to Dose Limiting Toxicity Assessment for Unrelated Adverse Event
THOMSON REUTERS  ·  08-27
Portage Biotech- Plan to Replace 1 Patient in Adport-601 Trial Who Withdrew Prior to Dose Limiting Toxicity Assessment for Unrelated Adverse Event
Press Release: Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
Dow Jones  ·  08-27
Press Release: Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
Portage Biotech Releases Q2 2024 Financials
TIPRANKS  ·  08-27
Portage Biotech Releases Q2 2024 Financials
Wall Street Set to Open Higher Friday as Investors Await Fed Chair Powell's Jackson Hole Speech
MT Newswires Live  ·  08-23
Wall Street Set to Open Higher Friday as Investors Await Fed Chair Powell's Jackson Hole Speech
Investors Await Fed Chair Powell's Jackson Hole Speech as US Futures Rise in Friday's Premarket
MT Newswires Live  ·  08-23
Investors Await Fed Chair Powell's Jackson Hole Speech as US Futures Rise in Friday's Premarket
Investors Await Fed Chair Powell's Jackson Hole Speech as US Futures Rise in Friday's Premarket
MT Newswires Live  ·  08-23
Investors Await Fed Chair Powell's Jackson Hole Speech as US Futures Rise in Friday's Premarket
Portage Biotech Navigates Strategic Changes Amid Loss Reduction
TIPRANKS  ·  08-15
Portage Biotech Navigates Strategic Changes Amid Loss Reduction
Portage Biotech Reports FY24 Net Result Of $(75.4)M Vs $(104.7)M Last Year; Says Discontinuing iNKT Clinical Trial For PORT-2; Continues To Explore Strategic Alternatives, Including Restructurings (Both In And Out Of Court)
Benzinga  ·  08-15
Portage Biotech Reports FY24 Net Result Of $(75.4)M Vs $(104.7)M Last Year; Says Discontinuing iNKT Clinical Trial For PORT-2; Continues To Explore Strategic Alternatives, Including Restructurings (Both In And Out Of Court)

Introduction

Company Name.
Portage Biotech Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
Issue price:
--